CA
ACRS icon

Clearstead Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Clearstead Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32 Buy
+6
New +$27 ﹤0.01% 3539
2025
Q4 		– Sell
-1
Closed -$2 – 2740
2025
Q3 		$2 Buy
+1
New +$2 ﹤0.01% 3075

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Clearstead Advisors's ACRS Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 6 shares worth $32. The stake represents ﹤0.01% of the portfolio and ranks #3539 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in ACRS as recently as Q3 2025.

Clearstead Advisors first reported a position in ACRS in Q3 2025 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Clearstead Advisors held 6 shares of Aclaris Therapeutics worth $32 as of Q2 2026.
  • Aclaris Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3539 holding.
  • Clearstead Advisors first reported a position in Aclaris Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.